

## Neuropathic Pain Treatment Gives Avigen New Lease on Life and Neuromed Follows the Snail Trail

Wendy Wolfson

DOI 10.1016/j.chembiol.2007.05.003

(Chemistry & Biology 14, 341–343; April 27, 2007)

In the Innovations article published in the April issue of *Chemistry & Biology*, it should be noted that the sentence “AV411 is now in a phase II trial in Australia (which recognizes Japanese drug designations) and is undergoing a phase I trial in the U.S.” should read “AV411 has completed a Phase I trial and is now in a Phase II trial in Australia (which recognizes Japanese drug designations).” The sentence “So far, Avigen has conducted a 12 week phase I safety and efficacy trial” should read “So far, Avigen has conducted a Phase I trial.” Lastly, Avigen’s anticipated burn rate is \$25–\$28 million per year, not \$20 million as printed.